Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. - Wikidata - thesis-toulmin - TriplyDB

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

http://www.wikidata.org/entity/Q42802665

about

PAX3-FOXO1 fusion gene in rhabdomyosarcoma MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development Analysis of molecular cytogenetic alteration in rhabdomyosarcoma by array comparative genomic hybridization Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.Pediatric Rhabdomyosarcoma.Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.Conditional activation of MET in differentiated skeletal muscle induces atrophy.Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma MET receptor is a potential therapeutic target in high grade cervical cancer Childhood rhabdomyosarcoma: recent advances and prospective views.The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma Advances in sarcoma genomics and new therapeutic targets.PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.Molecular profiling of childhood cancer: Biomarkers and novel therapies EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma Adult human sarcomas. II. Medical oncology.Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.Clinical relevance of molecular genetics to paediatric sarcomas Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.Capture and printing of fixed stromal cell membranes for bioactive display on PDMS surfaces The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.Differentiation rather than aging of muscle stem cells abolishes their telomerase activity.Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.Molecular and cellular biology of rhabdomyosarcoma.Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.Pharmacotherapy for pediatric soft-tissue sarcomas.RNAi: a potential new class of therapeutic for human genetic disease.Caveolins in rhabdomyosarcoma

P2860

Q24646520-8D2002BD-1647-43E5-AE53-0D617AC9D969 Q24648202-23927851-8202-4328-ADB7-81377978F539 Q28537996-AE9B2185-74CE-4957-A9C8-BE47DCFD7701 Q28546245-1B35F26A-7A21-48C8-B9C8-0D58E0C206E7 Q30009946-AF59DBEC-D2F1-4500-BEF4-B3CA58760F38 Q33615694-D4EE6F06-45EE-411F-BD6F-B191C7071CD1 Q33842070-424CFEAB-AD6B-4183-93BB-9C34B14AC6DD Q33901521-0D25A18F-6AC3-4008-BB3F-64EDCB6719DB Q34028460-6011646A-BCA8-49A4-886F-FBD94B2C2C81 Q34461690-7EFEB0FA-4256-40C1-9187-90B59900E2A1 Q34494731-28CD1641-0D71-47F7-ABBC-3AE35319F6C5 Q34595811-3E41ED32-6ADD-41D3-9965-68697A395802 Q35082747-24952077-8961-40B1-BFDE-8FD0C1790D0D Q35723439-A3E84EB4-CF9D-463F-98FF-DA6869F56400 Q35832923-2957F007-18AD-418A-A198-3858DAFE0D95 Q35847829-6BAB2501-EB70-4B3E-9B96-3C9E9385385A Q35904618-43A87A0F-4436-4B34-8AB1-F8180104D28C Q35993346-3BB8CFD7-1ACD-491E-A62F-5487D4D45B2E Q36156793-C715521E-884F-4CC3-9B2E-AD8EC2C6157F Q36250783-7DBA9B79-6635-4AFC-9D6D-E8F461254D20 Q36310662-689C9AE5-4065-4DC8-9C4C-DEC8A6443324 Q36481029-1B984A9D-EB49-488A-B8B5-D7637BA3E610 Q36588372-3BACF5D9-70D2-43DC-920B-3C0DBD9E17F3 Q36717196-91D822C4-682E-46BF-9941-53774A217CD6 Q36731430-0B146462-714A-46AE-AA6B-00FAE94E2D02 Q36739725-F247415F-2BCC-4467-842B-488C6E170368 Q36806186-17A45E8E-6BFB-4E54-A27C-9D593046EF77 Q36820041-74B77302-DFA3-4477-A97A-C81CFD21DEE9 Q36924325-6A2D1CAD-D289-4162-A50B-DBB401640CAC Q37213138-9EBA25FF-15FF-4150-8F4E-C2E6484959DA Q37286651-7EF8BA12-9AF4-4B21-8B84-A97E6667851F Q37337884-4B052778-2728-491C-BB0E-9B6861081E20 Q37351695-A6F5688D-9E1D-48FC-A3FF-E88ED1BA60C3 Q37464647-57968409-CC9D-429D-B982-CCE1E8F771E2 Q37544362-339F2CC2-0B26-41FA-8DC8-F9E94254B71D Q37630588-0D9BB43A-F630-42CC-A796-F7A10B902CD8 Q37831148-FA3ED6ED-1D65-4841-905B-8DA64A979BB6 Q37838445-B7A28728-F92C-4C3E-B958-3B35F14889C8 Q37871417-EA640D11-7A91-4446-ACF3-B5C0FD8EFFA0 Q37894860-00E22026-3236-43FA-BEF0-9638619F9503

P2860

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

http://www.wikidata.org/entity/Q42802665

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@en

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@nl

type

label

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@en

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@nl

prefLabel

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@en

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

@nl

P1433

Q42802665-C6171674-E386-428C-9563-D67D41FADBD5

P1476

Q42802665-A12F9DF9-EE18-4653-90EF-81951F1BFD73

P2093

Q42802665-0ED98BFB-6354-45ED-A382-D4C3633567E8

Q42802665-4A8EA8AA-6101-404F-A4FE-1570A4F356CD

Q42802665-51274546-170C-479B-8D6D-930855502C06

Q42802665-689134C5-5F30-4D7D-A88B-D706ECA7D9EB

Q42802665-773FB5D7-FFD2-4F7A-AFF8-653F1FA2157A

Q42802665-9064D06C-BF77-42E0-8B5A-5E10CE7037B2

Q42802665-9D9644B4-8197-4431-9A8E-A321EB371385

Q42802665-DA8337F1-D454-4EBC-B9E5-4A2D2876C936

P304

Q42802665-30F6B7B1-0573-46A4-92C3-CD19FB3776C1

P31

Q42802665-AF7E2600-8DEA-4BC1-B778-2252B9DAA4E3

P356

Q42802665-DEDD396B-B25C-469D-95E0-F7C6DE012106

P407

Q42802665-7DEBBE35-4E3C-41BD-BB1B-95B5D0BB32B1

P433

Q42802665-DE8762AB-38A1-4061-AE4F-B9113C2FE7FE

P478

Q42802665-92F90EE8-93B0-42AC-B86B-A3936B00D32F

P50

Q42802665-48D9793D-ABC1-4271-8F4B-6A6A130A0062

Q42802665-7588F821-8FEE-4388-AD0B-A1B51F7F6D55

Q42802665-B7C14AF7-5DE7-4248-B4E1-11BD15E2CFB2

P577

Q42802665-E92DBD89-595D-4EAB-9C6C-8AE3EFB4EE97

P698

Q42802665-048E326E-AC01-40CB-B83A-7044AD64A9E1

P356

0008-5472.CAN-05-4292

P1433

Cancer Research

P1476

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma

@en

P2093

Alberto Grinza

http://www.w3.org/2001/XMLSchema#string

Carola Ponzetto

http://www.w3.org/2001/XMLSchema#string

Claudio Scuoppo

http://www.w3.org/2001/XMLSchema#string

Francesca Bersani

http://www.w3.org/2001/XMLSchema#string

Michel Schmitt-Ney

http://www.w3.org/2001/XMLSchema#string

Paola Allegra

http://www.w3.org/2001/XMLSchema#string

Paolo Accornero

http://www.w3.org/2001/XMLSchema#string

Silvia Miretti

http://www.w3.org/2001/XMLSchema#string

P304

4742-4749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-4292

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Riccardo Taulli

Paolo Emanuele Forni

Tiziana Crepaldi

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16651427

http://www.w3.org/2001/XMLSchema#string